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Abstract
Objective. To determine the presence and spatial distribution of
different macrophage phenotypes, governed by granulocyte
macrophage colony-stimulating factor (GM-CSF) and macrophage
colony-stimulating factor (M-CSF) skewing signals, in giant cell
arteritis (GCA) lesions. Methods. Temporal artery biopsies (TABs,
n = 11) from treatment-naive GCA patients, aorta samples from
GCA-related aneurysms (n = 10) and atherosclerosis (n = 10) were
stained by immunohistochemistry targeting selected macrophage
phenotypic markers, cytokines, matrix metalloproteinases (MMPs)
and growth factors. In vitro macrophage differentiation (n = 10)
followed by flow cytometry, Luminex assay and ELISA were
performed to assess whether GM-CSF and M-CSF are drivers of
macrophage phenotypic heterogeneity. Results. A distinct spatial
distribution pattern of macrophage phenotypes in TABs was
identified. CD206+/MMP-9+ macrophages were located at the site
of tissue destruction, whereas FRb+ macrophages were located in
the inner intima of arteries with high degrees of intimal
hyperplasia. Notably, this pattern was also observed in
macrophage-rich areas in GCA aortas but not in atherosclerotic
aortas. Flow cytometry showed that GM-CSF treatment highly
upregulated CD206 expression, while FRb was expressed by M-
CSF-skewed macrophages, only. Furthermore, localised expression
of GM-CSF and M-CSF was detected, likely contributing to
macrophage heterogeneity in the vascular wall. Conclusions. Our
data document a distinct spatial distribution pattern of CD206+/
MMP-9+ macrophages and FRb+ macrophages in GCA linked to
tissue destruction and intimal proliferation, respectively. We
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suggest that these distinct macrophage phenotypes are skewed
by sequential GM-CSF and M-CSF signals. Our study adds to a
better understanding of the development and functional role of
macrophage phenotypes in the pathogenesis of GCA and opens
opportunities for the design of macrophage-targeted therapies.
Keywords: giant cell arteritis, granulocyte macrophage colony-
stimulating factor, macrophages, macrophage colony-stimulating
factor, vasculitis
INTRODUCTION
Giant cell arteritis (GCA) is an inflammatory
disorder and the most frequent form of vasculitis.
GCA affects the medium and large vessels and
occurs exclusively in elderly individuals.1 Patients
with GCA present with various symptoms,
depending on which arteries are affected.2
Inflammation of cranial arteries (e.g. the temporal
artery) often leads to headache but can also cause
ischaemic symptoms such as jaw claudication and
vision loss. Large arteries such as the aorta can
also be affected, although symptoms of large-
vessel GCA are often nonspecific, which may lead
to diagnostic delay.3 Without proper treatment,
large-vessel GCA can cause aortic aneurysm and
dissection as a result of chronic damage to the
vascular wall.4 Glucocorticoids (GCs) remain the
main treatment option for GCA patients, although
novel GC-sparing therapies have recently become
available, such as tocilizumab (IL-6 receptor
blockade).5
The pathology of GCA is characterised by a
granulomatous infiltrate in the vessel wall, which
mainly consists of T cells and macrophages.1
However, the trigger of this process is still unclear.
It is generally thought that resident dendritic cells
in the vessel wall, after pattern recognition
receptor stimulation, become activated and start
producing cytokines and chemokines that attract
T cells into the vessel wall. Activated T cells
produce cytokines and growth factors that
activate the vascular smooth muscle cells, which in
turn produce CCL2 and CX3CL1, recruiting
monocytes to the lesion. These monocytes
differentiate into macrophages upon entering the
tissue.1,6 Some of the macrophages fuse and
develop into multinucleated giant cells.7
Macrophages in GCA lesions are derived from
circulating monocytes, of which three subsets
have been identified: classical CD14highCD16
cells, intermediate CD14highCD16+ cells and non-
classical CD14dimCD16+ cells.
Macrophages are the main producers of
proinflammatory cytokines, growth factors and
tissue-destructive molecules, including matrix
metalloproteinases (MMPs),8 which enhance
inflammation, cause damage to the lamina
elastica9 and contribute to vessel wall remodelling
and intimal hyperplasia. Infiltration and cellular
proliferation in the intimal layer of the artery
ultimately lead to occlusion, a process responsible
for the ischaemic symptoms.1 Recently,
macrophage-derived MMP-9 was reported to be
essential for T-cell infiltration into the vessel
wall.10 Macrophages also play a major role in the
skewing of T cells in the vessel wall by producing
polarising cytokines. T cells activated in the
presence of IL-12 and IL-18 develop into IFNc-
producing Th1 cells, whereas IL-1b, IL-6 and IL-23
lead to Th17 activation.11 GCA tissue displays a
mixed population of proinflammatory Th1 and
Th17 cells but essentially lacks Th2 cells or Tregs.1
Macrophages are incredibly plastic cells that can
switch phenotypes and functions depending on
environmental cues. The growth factors,
granulocyte macrophage colony-stimulating factor
(GM-CSF) and macrophage colony-stimulating
factor (M-CSF), were shown to skew macrophages
into different phenotypes.12 CD206 (mannose
receptor), a macrophage marker associated with
tissue remodelling, was found to be highly
upregulated on GM-CSF-primed macrophages.13
Alternatively, folate receptor b (FRb) has been
described as a marker of M-CSF-induced
differentiation.14 FRb+ macrophages have been
associated with fibroblast activation and
proliferation in rheumatoid arthritis.15 Fibroblast
proliferation is also a key finding in the intimal
layer in GCA and eventually leads to luminal
occlusion. Whether macrophages from GCA
patients respond similarly to GM-CSF and M-CSF
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skewing signals needs to be elucidated. Moreover,
the expression of GM-CSF and M-CSF in GCA
lesions and their relation to macrophage
heterogeneity has not yet been assessed.
Although macrophages are one of the
dominant inflammatory cellular infiltrates in GCA
lesions,6,16–19 little is known about their
phenotypic heterogeneity and spatial distribution
within the affected vessel wall. We hypothesised
that within GCA lesions, distinct macrophage
phenotypes are associated with distinct functions
and lesion morphology, dictated by local GM-CSF
and M-CSF production. To address this hypothesis,
we first comprehensively characterised
macrophage phenotypes in affected temporal
artery biopsies (TABs) and aortic samples from
GCA patients, in relation to lesion morphology. To
this end, we used a panel of established
macrophage polarisation markers and
inflammatory factors. Next, to investigate whether
GM-CSF and M-CSF signals are crucial drivers of
macrophage polarisation, their effects on
macrophage differentiation and phenotypes were
determined in vitro. In addition, we assessed the
expression of GM-CSF and M-CSF in GCA lesions.
RESULTS
Leucocyte infiltrates detected in different
compartments of the arterial wall in GCA-
affected temporal arteries, GCA-affected
aortas and atherosclerotic aortas
Transmural inflammation was found in all GCA-
positive TABs, whereas no leucocyte infiltrates
were found in the non-inflamed control TABs
(Supplementary figure 1a and b). GCA-positive
TABs presented with a high degree of intimal
hyperplasia and luminal occlusion, whereas
control TABs presented with no or minimal
intimal hyperplasia. In the aortas from patients
diagnosed with GCA, infiltrating leucocytes were
found mainly in the adventitial and medial layers
of the vessel wall (Supplementary figure 1c). The
infiltrates in the media of the GCA aorta often
formed a granulomatous rim around necrotic
areas. This granulomatous infiltration pattern was
not found in atherosclerotic aortas. In
atherosclerotic aortas, however, adventitial
infiltrates and massive intimal infiltrates
surrounding plaques with minimal medial
infiltration were found (Supplementary figure 1d).
Distinct spatial distribution patterns of
different macrophage phenotypes in GCA-
affected TABs
In GCA TABs, markers of tissue remodelling
macrophages were expressed in different layers
of the vessel wall (Figure 1a–d and
Supplementary figure 2 for all isotype controls).
CD206 positivity was found mainly in the media,
adventitia-media and media-intima borders
(Figure 1a). Interestingly, MMP-9 staining was
also positive in CD206-positive regions, suggesting
that CD206+ macrophages express MMP-9
(Figure 1b). In contrast, FRb-positive cells were
mainly found in the adventitia and inner intima
but rarely in the media (Figure 1c).
Proinflammatory markers CD64, CD86, IL-12, IL-23,
IL-6 and IL-1b (Figure 1e–j, respectively) were
strongly expressed in all three layers of the vessel
wall, most prominently in the adventitia.
Additionally, MMP-2 was detected mainly in the
adventitia and the media (Figure 1d). This
suggests that all macrophages in the vessel wall
express CD64 and are capable of producing
proinflammatory cytokines, but concomitantly
express different tissue remodelling markers in
specific compartments of the lesions.
Expression of CD64, FRb, CD206 and MMP-9
exclusively colocalised with PU.1 staining
(Supplementary figure 3). PU.1, a transcription
factor highly expressed in macrophages, was
selected for double staining as it is found in cell
nuclei, thereby facilitating visualisation of
colocalisation with the cytoplasmic and membrane
staining patterns of the other markers. Double
staining of CD68 with PU.1 (Supplementary figure 3)
showed that the vast majority of PU.1-positive cells
in TABs also expressed CD68, indicating that these
cells are indeed macrophages. Although PU.1 can be
expressed by mast cells, granulocytes, osteoclasts
and Th9 cells, these cells are rarely found in GCA
lesions while macrophages account for the majority
of PU.1-positive cells in GCA-affected vessel walls. In
contrast, some cells expressing the proinflammatory
cytokines IL-12 and IL-23 stained negative for PU.1,
indicating that besides macrophages, other
infiltrating or tissue-resident cells are also able to
express these cytokines.
Analysis of consecutive tissue stainings revealed
a distinct distribution pattern of tissue
remodelling markers in specific areas of the vessel
(Supplementary figure 4a). More specifically,
CD206+/MMP-9+ macrophages were mainly found
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
2020 | Vol. 9 | e1164
Page 3
WF Jiemy et al. Macrophage heterogeneity in GCA
along the media and its borders, whereas FRb+
macrophages were dominant in the inner intima
and in the adventitia, areas adjacent to CD206+
macrophages. Triple-fluorescence staining
confirmed that only a subpopulation of CD68+
macrophages, located in the media and its
borders, expressed CD206 and that MMP-9
expression exclusively colocalised with these
CD206+ macrophages (Figure 2). The latter would
be in line with a tissue-invasive role of CD206+/
MMP9+ macrophages. Semiquantitative analysis of
the tissue stainings further corroborated the
distinct spatial distribution pattern of CD206+/
MMP9+ and FRb+ macrophages in the GCA vessel
wall (Figure 3).
Distribution pattern of macrophage
phenotypes in GCA-affected aortas and
atherosclerotic aortas
All surface markers and cytokines were found to
be abundantly expressed in both GCA and
atherosclerotic aortas, albeit in different layers
(Figure 3). The distinct pattern of different
macrophage phenotypes found in GCA-affected
TABs was also found in the media of GCA-
affected aortas (Supplementary figure 4b). In the
granulomatous rim, around sites of tissue necrosis,
CD206+/MMP-9+ macrophages were surrounded by
FRb+ macrophages. This distinct pattern of
macrophage phenotypes, however, was not found
Figure 1. Expression of macrophage phenotypic markers, proinflammatory cytokines and matrixmetalloproteinases in GCA TABs. Single-staining
immunohistochemistry showed the expression of CD206 (a, a*), MMP-9 (b, b*), FRb (c, c*), MMP-2 (d, d*), CD64 (e, e*), CD86 (f, f*), IL-12
(g, g*), IL-23 (h, h*),IL-6 (i, i*) and IL-1b (j, j*). Representative stainings are shown. Red box indicates zoomed region. Zoomed figures (*). GCA,
giant cell arteritis; TAB, temporal artery biopsy.
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in atherosclerotic aortas (Supplementary figure
4c). Macrophages around atherosclerotic plaques
showed a mixed phenotype, with an overlapping
expression of CD64, CD206 and FRb without a
distinct distribution pattern.
GM-CSF and M-CSF contribute to
macrophage phenotypic differences
As GM-CSF and M-CSF are known to influence
macrophage phenotypes, we hypothesised that
they play a key role in skewing macrophage
phenotypes in GCA lesions. To test this hypothesis,
we investigated the effects of GM-CSF and M-CSF
on the phenotype of monocyte-derived
macrophages in vitro. GM-MØs and M-MØs from
healthy donors and GCA patients were analysed
for expression of CD64, CD86, CD206 and FRb by
flow cytometry. The culture supernatant was
analysed for IL-1b, IL-6, IL-12, IL-23 and MMP-9.
CD206 expression was found to be significantly
higher on GM-MØs compared to M-MØs
(Figure 4a and c). FRb, however, was expressed
only on M-MØs. Additionally, also CD64 and CD86
levels were higher on M-MØs (Figure 4c).
Compared to unstimulated monocyte subsets,
both GM-MØs and M-MØs displayed an increased
per-cell expression of CD206, CD64 and CD86
(Supplementary figure 5). GM-CSF signalling
appeared to downregulate FRb expression, as FRb
was expressed by monocytes but not by GM-MØs.
Although clear phenotypic differences were
observed by flow cytometry, only minor
differences in cytokine production were found.
While IL-6, IL-23 and MMP-9 production were
detected in supernatants (Figure 4b), IL-12 and IL-
1b production were not (data not shown). IL-6
levels were found to be significantly higher in the
GM-MØ supernatants than in the M-MØ
supernatants in both GCA and HCs (Figure 4b and
Figure 2. MMP-9 is exclusively expressed by CD206+ macrophages in the media and media borders. Shown are the single-staining
immunohistochemistry of CD206 and the triple-fluorescence staining of CD68 (red), CD206 (green) and MMP-9 (yellow) on GCA TAB.
Colocalisation of CD68, CD206 and MMP-9 is shown in cyan. A, Adventitia; GCA, giant cell arteritis; I, Intima; M, Media; TAB, temporal artery
biopsy.
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c). For both GCA and HCs, MMP-9 production was
found to be significantly higher in M-MØs than in
GM-MØs.
Additionally, the phenotypic differences
observed in macrophages from GCA patients may,
to some extent, already be present in circulating
monocytes. By flow cytometry, differences in the
expression of these markers on monocyte subsets,
defined by CD14 and CD16 expression, were
indeed observed (Supplementary figure 5).
Interestingly, we found elevated expression of
CD64 on classical and intermediate monocyte
subsets from GCA patients compared to HCs. In
contrast, FRb expression on classical and
intermediate monocytes from GCA patients was
significantly lower compared to those from HCs.
Although CD206 expression on monocyte subsets
was not modulated in patients, CD206 expression
was higher in GCA GM-MØs and GCA M-MØs
than in their counterparts from HCs. Thus,
circulating monocytes from GCA patients
demonstrate a phenotype reminiscent of GM-CSF-
stimulated macrophages.
Local GM-CSF and M-CSF expression
patterns may link to the distinct
macrophage distribution pattern in GCA
lesions
As we observed distinct effects of GM-CSF and M-
CSF on macrophage surface marker expression, we
performed IHC for GM-CSF and M-CSF on GCA-
affected TABs and aortas. These experiments
revealed that GM-CSF is dominantly expressed by
infiltrating leucocytes and endothelial cells in the
adventitial layer of GCA TABs (Figure 5a). In
contrast, M-CSF was found to be abundantly
expressed at the site of the CD206+/MMP9+
macrophages at the intima-media borders in TABs.
These findings were substantiated by
semiquantitative scoring showing the highest M-
CSF score in the media-intima of TABs (Figure 5b).
Figure 3. Localisation of proinflammatory and tissue remodelling markers in GCA TABs, GCA aortas and atherosclerotic aortas. Expression of
surface markers, cytokines and matrix metalloproteinases (MMPs) in GCA-affected TABs (n = 11, for CD206 n = 9), (a), GCA-affected aortas
(n = 10), (b) and atherosclerotic aortas (n = 10), (c) was semiquantitatively scored. Data are presented as median with interquartile range. The
intimal layer of GCA aortas and the medial layer of atherosclerotic aortas were not scored because of a lack of infiltrating cells. GCA, giant cell
arteritis; MMP, matrix-metalloproteinase; TAB, temporal artery.
2020 | Vol. 9 | e1164
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In the aorta, GM-CSF was only weakly expressed
in medial granulomas, whereas M-CSF was highly
expressed at the site of the CD206+ macrophages
surrounding the necrotic areas (Figure 5a).
To assess the production of GM-CSF and M-CSF
by skewed macrophages, we performed real-time
qPCR on total mRNA from GM-MØs and M-MØs
(derived from HCs). We observed significantly
higher expression of M-CSF transcripts in GM-MØs
than in M-MØs (Figure 5c). GM-CSF transcripts,
however, were not detected. This finding is in line
with the tissue staining experiments, where M-CSF
was found expressed at the site of the CD206+
macrophages in the media and media borders,
suggesting that these macrophages produce M-CSF.
As CD206 expression was observed to be higher
in GCA GM-MØs and M-MØs than in their HC
counterparts, we reasoned that per-cell expression
of the GM-CSF and M-CSF receptors might be
modulated in GCA monocytes. This, however, did
not appear to be the case in peripheral blood
monocyte subsets from HCs and GCA patients, in
which no differences were found (Figure 5d).
Taken together, our data suggest that the
expression pattern of GM-CSF and M-CSF in GCA
lesions is different and may contribute to the
spatial distribution of macrophage phenotypes in
GCA lesions. M-CSF produced by CD206+
macrophages is likely to prime adjacent
macrophages to express FRb.
Figure 4. Macrophage surface marker expression and cytokine production depend on GM-CSF and M-CSF signals. Mean fluorescence intensity
of CD206 and FRb on GM-CSF-differentiated macrophages (GM-MØs) and M-CSF-differentiated macrophages (M-MØs) from GCA patients
(n = 10) and healthy controls (n = 10) (a). Luminex assay (normalised per 50 000 cells) of IL-6, IL-12 and MMP-9 in culture supernatants of GM-
MØs and M-MØs from GCA patients (n = 10) and healthy controls (n = 10) (b). Heat map showing relative expression of the markers on GM-
MØs compared to M-MØs (c). GCA, giant cell arteritis.
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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Figure 5. GM-CSF and M-CSF signalling in GCA tissues, macrophages and monocyte subsets. Tissue expression of GM-CSF and M-CSF in the
temporal artery (TAB) and aorta biopsy tissues from GCA patients (a). In the TABs, regions of interest (red) are magnified and shown in the lower
right corner. In (b), semiquantitative scores for GM-CSF and M-CSF in GCA TABs (n = 11) are displayed. The relative GM-CSF and M-CSF gene
expression of healthy donor PBMC-derived GM-MØs and M-MØs (n = 8 each, qPCR was performed in triplicates) normalised to b-actin are
shown in (c). In (d), the mean fluorescence intensity of the GM-CSF receptor and the M-CSF receptor in PBMC-derived monocytes from healthy
controls (HC) and GCA patients (n = 10 each) is shown. GCA, giant cell arteritis; GM-MØ, GM-CSF macrophages; M-MØ, M-CSF macrophages;
TAB, temporal artery biopsy.
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Macrophage FRb positivity in the inner
intima is associated with intimal
hyperplasia
FRb positivity was found in the inner intima of
the TAB, this is the region where intimal
proliferation occurs. To determine whether the
extent of FRb positivity was associated with the
severity of intimal hyperplasia, we divided luminal
occlusion in GCA-affected TABs into mild or
massive occlusion based on the intimal thickness
score (Figure 6a) and related this factor to the
extent of FRb positivity. Indeed, FRb expression
was higher in the inner intima region of TABs
with massive intimal hyperplasia (Figure 6b).
Growth factors such as platelet-derived growth
factor (PDGF) could contribute to intimal
hyperplasia. To investigate whether FRb+
macrophages could be a source of PDGF, we
performed macrophage differentiation and
activation experiments followed by ELISA for
PDGF-AA in the culture supernatant. Our results
showed that M-MØs produced significantly higher
concentrations of PDGF-AA compared to GM-MØs
(Figure 6c), in both GCA and HC groups. Our data
suggest that M-MØs, resembling the FRb+
macrophages indeed have the capacity to produce
higher levels of a growth factor-promoting
intimal hyperplasia.
DISCUSSION
In this study, we revealed a distinct spatial
distribution of macrophage phenotypes in GCA-
affected vessel walls and provide evidence that
macrophage phenotypic heterogeneity is
influenced by the growth factors GM-CSF and M-
CSF. Moreover, distinct macrophage phenotypes
were associated with tissue destruction and
intimal hyperplasia. Although it has been
suggested previously that macrophages have
different functions in different compartments of
the inflamed vessel wall in GCA,17 our study is the
first to assign different macrophage phenotypes
to defined regions of the vessel wall based on a
broad selection of macrophage markers.
Our data demonstrate that macrophages in
GCA-affected TAB show a distinct expression
Figure 6. FRb+ positivity in the inner intima is associated with high-degree intimal hyperplasia. Classification of mildly and massively occluded
TAB based on the thickness of intima (a). The Mann–Whitney U-test showed significantly higher expression of FRb in the inner intima of TABs
with massive intimal hyperplasia (mild occlusion n = 6; massive occlusion n = 5) (b). The Wilcoxon signed-rank test showed higher expression of
PDGF-AA in M-MØ compared to GM-MØ (n = 10 each, ELISA was performed in duplicates for each sample) (c). GCA, giant cell arteritis; GM-
MØ, GM-CSF macrophages; M-MØ, M-CSF macrophages; TAB, temporal artery biopsy.
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pattern of surface markers depending on their
location in the tissue. Macrophages with a
proinflammatory phenotype, including expression
of Th1- or Th17-skewing cytokines, were detected
throughout the vessel wall. CD206+/MMP-9+
macrophages were mainly found in the media
and media borders along the sites of lamina
elastica degradation which is in line with a
previous report that MMP-9-producing
macrophages are located in the media borders.8,10
Diversely, FRb-expressing macrophages were
mainly found in regions adjacent to the CD206+
macrophages.
Our data suggest a role for GM-CSF and M-CSF
in macrophage phenotypic heterogeneity in GCA
lesions. Previously, CD206 and FRb were found to
be markers for GM-CSF- and M-CSF-differentiated
macrophages, respectively.13,14 Our in vitro
differentiation data confirmed that GM-MØs
indeed have high expression of CD206 and lack
expression of FRb. In contrast, FRb expression was
exclusively upregulated in M-MØs. Additionally,
GM-CSF has been reported to diminish FRb
expression by macrophages even when
differentiated in the presence of both GM-CSF
and M-CSF.14 These findings suggest that CD206+
macrophages in the media and media borders are
mainly primed by GM-CSF, while FRb+
macrophages adjacent to CD206+ macrophages
are primed by M-CSF. This also implies a gradient
of GM-CSF and M-CSF production in different
layers of the vessel wall that may be responsible
for the distinct macrophage phenotype
distribution observed. GM-CSF expression was
found highest in the adventitia and was mainly
expressed by endothelial cells and infiltrating
leucocytes, presumably activated T cells and B
cells.20,21 In contrast to GM-CSF, M-CSF expression
was localised at the site of medial CD206+/MMP9+
macrophages. GM-CSF can induce M-CSF
production, as previously demonstrated in
monocytes22 and confirmed by our qPCR data
(Figure 5c). Additionally, a recent study showed
upregulated expression of GM-CSF receptor in
GCA-affected temporal arteries.23 Furthermore,
GM-CSF in combination with IFNc has been
reported to significantly increase macrophage
fusion into giant cells,24 the hallmark of GCA.1
Based on our immunohistochemical stainings, we
found that multinucleated giant cells in GCA
lesions are CD206+ and are located at the site of
medial destruction.
We found significantly higher expression of FRb
in the inner intima in TABs with a higher degree
of intimal hyperplasia. This finding suggests that
FRb macrophages may play a role in myofibroblast
activation, migration and proliferation, leading to
intimal hyperplasia. Indeed, improvement of
pulmonary fibrosis was shown by depleting FRb+
macrophages.25 FRb expression has previously
been reported in the adventitia of GCA TABs.26
Here, we showed that FRb is also expressed in the
inner intima. This discrepancy can be explained by
differences in the degree of intimal hyperplasia in
the TABs between studies. Mechanistically, FRb+
M-MØs in the inner intima may contribute to
intimal hyperplasia by increased growth factor
production such as PDGF-AA.27 PDGF-AA is
expressed in GCA lesions and could contribute to
myofibroblast activation, migration and
proliferation.28,29 Other growth factors such as
FGFs, PDGF-CC and PDGF-DD could also
potentially play a role in promoting intimal
hyperplasia, although their relation to FRb+
macrophages in GCA remains to be elucidated.
Macrophage heterogeneity in GCA lesion could
be influenced by step-wise GM-CSF and M-CSF
signals. Recently, Watanabe et al.30 proposed two
nonmutually exclusive pathways by which
monocyte-derived macrophages contribute to
tissue injury and repair. In the first pathway,
tissue-infiltrating monocytes progressively
differentiate from proinflammatory macrophages
into proresolving macrophages depending on
signals they encounter within the local
microenvironment. In the second pathway, the
proinflammatory macrophages disappear once the
inflammatory trigger has been cleared. A second
wave of monocytes then enters the tissue, which
differentiates into proresolving macrophages in
response to the environmental cues. Based on our
data, we propose a potential pathogenic model
of GCA involving sequential macrophage
differentiation events (Figure 7). In this model,
infiltrating monocytes are initially primed by GM-
CSF, after which they differentiate into CD206+
macrophages. These GM-MØs then migrate to the
media and media borders, exerting their tissue-
invasive, digestive and proangiogenic effects.
Additionally, these CD206+ GM-MØs release large
amounts of M-CSF, which in turn primes the
macrophages surrounding them to express FRb.
These FRb+ macrophages then boost myofibroblast
migration and proliferation, possibly by higher
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production of growth factors (such as PDGF-AA).
This process eventually leads to luminal occlusion.
In contrast to our tissue staining results, MMP-9
production was found to be higher in M-MØ than
in GM-MØ. This result may be explained by the
limitations of the in vitro differentiation model.
Indeed, the GCA tissue environment is much more
complex and enriched with a multitude of
cytokines. Cytokines such as IFNc, which is highly
expressed in GCA lesions,31 could further
modulate the expression of surface markers,
cytokines and MMPs. Indeed, it has been reported
that IFNc synergises with GM-CSF to increase
MMP-9, IL-12 and IL-1b production in
macrophages.32–34
A distinct macrophage distribution pattern was
also observed in GCA-affected aortas but not in
atherosclerotic aortas. In contrast to TABs, a
distinct macrophage distribution pattern was
observed only within the media of the GCA
Figure 7. Model of step-by-step giant cell arteritis (GCA) pathogenesis in the temporal artery involving GM-CSF and M-CSF. The following steps
occur in early-stage GCA. (1) Monocytes enter the vessel wall. (2) Infiltrating monocytes are primed by GM-CSF produced by T cells, B cells and
endothelial cells, after which they differentiate into CD206+ GM-MØs. (3) These CD206+ GM-MØs then migrate to the media and media borders,
exerting their tissue-invasive, digestive and proangiogenic capabilities. In late-stage GCA, the following steps occur. (4) CD206+ GM-MØs release
large amounts of M-CSF, which in turn primes the macrophages surrounding them to express FRb. (5) FRb+ macrophages release high
concentrations of growth factors that activate myofibroblasts, promoting their migration to the intima and (6) inducing their proliferation, which
causes intimal hyperplasia and ultimately leads to luminal occlusion.
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aortas. The variation in this distribution pattern
between TABs and the aorta may be caused by
differences in vessel wall size and anatomical
build-up, as aortas have thicker media with
multiple lamina elastica layers. In contrast to GCA,
but confirming previous reports, macrophages in
atherosclerotic aortas were found mainly in the
intima surrounding the atherosclerotic plaques.35
These macrophages showed overlapping CD64,
CD206 and FRb expression. In line with our
findings of FRb positivity around atherosclerotic
plaques, reports have shown that partial M-CSF
depletion reduced atherogenesis36 and that M-
CSF-activated gene signatures are dominant in
early atherogenesis.37 We demonstrated that
CD206 did not colocalise with FRb+ macrophages
in GCA, whereas concomitant CD206/FRb
expression was shown in atherosclerosis
macrophages. The Th2 cytokine IL-4, highly
expressed in atherosclerotic lesions but to a
limited extent in GCA lesions, can upregulate
CD206 expression on FRb macrophages.31,38–40
Importantly, GM-CSF was reported to be
important in necrotic core formation in late-stage
atherogenesis.41 Overall, although macrophages
are abundant in both diseases, the environmental
cues governing macrophage phenotypes and
functions are different. For GCA, we propose a
sequential evolution of macrophage polarisation
that is initially driven by GM-CSF followed by M-
CSF signals, whereas the opposite sequence of
events occurs in atherogenesis.
We observed that circulating monocytes and
monocyte-derived macrophages from GCA
patients display a GM-CSF signature compared to
HCs. This finding was reflected by lower FRb
expression on monocytes and higher CD206
expression after differentiation into macrophages.
This also implies that monocytes from GCA
patients have a stronger response to GM-CSF.
However, we found no difference in GM-CSF
receptor expression between the groups.
Additionally, our previous study showed no
elevation of GM-CSF in the serum of GCA
patients,42 implying that other factors confer
increased sensitivity of GCA monocytes to GM-CSF.
The major strength of our study is the
comprehensive analysis of multiple markers of
inflammation and tissue remodelling, which
allows the identification of distinct macrophage
phenotypes. Our biopsy tissues were obtained
from treatment-naive patients to exclude the
potential effects of GCs on macrophage
phenotypes. Future studies should, however,
address the impact of GCs on the skewing of
lesional macrophage phenotypes. Finally, we also
included atherosclerotic aortas for comparison
and found that the roles of macrophages in the
pathogenic processes leading to these two
diseases are indeed different. We identified a
possible role for GM-CSF and M-CSF in the local
skewing of macrophage phenotypes in GCA and
substantiated this finding with in vitro
differentiation studies. We are aware that our
in vitro model does not fully capture the events in
the tissue, as a plethora of cytokines that can lead
to further skewing and activation of macrophages
were not explored. Future studies should focus on
expanding the proposed model to incorporate
additional activating cytokines and in vivo
intervention models.
Our study may aid in expanding current GCA
pathogenic models and identifying markers for
targeted therapy. Currently, a GM-CSF receptor-
blocking antibody, mavrilimumab (NCT03827018),
is being evaluated in a phase 2 clinical trial for
the treatment of GCA. Our findings add to the
rationale for targeting the GM-CSF receptor in
this disease. Additionally, reduced inflammation
was shown in a rheumatoid arthritis cartilage
explant model with a CD64-targeted
immunotoxin.43 Although further studies are still
needed, targeting CD206 might also prove to be
useful in reducing tissue destruction while
targeting FRb might prevent luminal occlusion in
GCA.
Taken together, vascular lesions of GCA patients
display a distinct spatial distribution pattern of
macrophage phenotypes associated with tissue
destruction and intimal hyperplasia that are likely
influenced by local expression of M-CSF and GM-
CSF. These findings contribute to improved
insights into the pathogenesis of GCA and lay the
foundation for designing new macrophage-
targeted therapies and imaging tracers.
METHODS
The data supporting the findings of this study are available
from the corresponding author on reasonable request.
Patients
Eleven inflamed TAB tissue samples of histologically proven
GCA collected before the start of GC treatment were
studied (Table 1). The diagnosis of GCA was based on a
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positive (panartertic) TAB, based on a pathologist’s
assessment or a positive 18F-fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography (PET-
CT) for GCA. In addition, non-inflamed TAB tissue from
patients who had (PET-CT-proven) GCA, isolated PMR
patients, and individuals who had neither GCA nor PMR
(n = 5 each) were included as controls. PMR was diagnosed
by a positive PET-CT for PMR. Clinical and laboratory data
for these patients were collected as part of our prospective
cohort study. The study was approved by the institutional
review board of University Medical Center Groningen
(METc2010/222). Written informed consent was obtained
from all study participants. All procedures were in
compliance with the Declaration of Helsinki.
Aorta tissues from GCA patients (n = 10) and age-
matched atherosclerotic controls (n = 10) were
retrospectively obtained after aortic aneurysm surgery
(Supplementary table 1). None of the patients used GCs at
the time of surgery. GCA was diagnosed after examination
of the aortic tissue by pathologists. The patients’ clinical
and laboratory data at the time of surgery were extracted
from medical records. Consent from the Internal Review
Board and written patient consent were not required under
Dutch law for human medical research (WMO) since the
tissue was obtained during necessary surgery. The patients
were informed about the study and agreed that the
obtained medical data could be used for research purposes
in accordance with privacy rules.
Frozen peripheral blood mononuclear cells (PBMCs) from
treatment-naive GCA patients (n = 10) and age- and sex-
matched healthy controls (HCs, n = 10) participating in the
prospective cohort study were used for in vitro studies
(Table 1). Additionally, for these patients, the GCA
diagnosis was confirmed by TAB and/or PET-CT. HCs were
screened by health assessment questionnaires, physical
examination and laboratory tests for past and actual
morbidities and excluded when they were not healthy
according to the adapted Senieur criteria.44
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded tissues were cut into
sections of 3 µm. The sections were deparaffinised and
rehydrated, followed by antigen retrieval in a 95°C water
bath (for buffers, see Supplementary table 1). For single
staining, tissues were incubated with primary anti-human
antibodies (Supplementary table 1), followed by
endogenous peroxidase blocking. The tissues were
subsequently incubated with secondary antibodies, 3-
amino-9-ethylcarbazole (DAKO, Glostrup, Denmark) for
peroxidase activity detection, and finally haematoxylin
(MERCK, Kenilworth, NJ, USA) as a counterstain. Matching
isotype controls were also included. For double staining
with the macrophage transcription factor PU.1, tissues were
simultaneously incubated with two primary antibodies
(Supplementary table 1). A MultiVision alkaline
phosphatase and horseradish peroxidase double-staining kit
(Thermo Fisher Scientific, Waltham, MA, USA) was used.
Reactive tonsil tissue was used as a positive control tissue
except for the detection of GM-CSF where spleen tissue was
used. All slides were scanned using a Nanozoomer Digital
Pathology Scanner (NDP Scan U 10074-01; Hamamatsu
Photonics K.K., Shizuoka, Japan).
Giant cell arteritis-positive TABs, GCA-positive aortas and
atherosclerotic aortas were semiquantitatively scored on a
five-point scale (0–4): 0 = no positive cells, 1 = occasional
positive cells (0–1% estimated positive), 2 = small numbers
of positive cells (> 1–20%), 3 = moderate numbers of
positive cells (> 20–50%), 4 = large numbers of positive cells
(more than 50%). An average score was calculated from
assessments by two independent investigators. Tissues were
scored in representative areas that contained infiltrating
cells, as GCA can contain skip lesions.45
Triple-fluorescence multispectral imaging
Paraffin sections were deparaffinised and rehydrated,
followed by antigen retrieval in Tris-EDTA buffer (pH 9) in a
95°C water bath for 45 min. Tissues were incubated for
5 min with TrueBlack Lipofuschin autofluorescence blocker
(Biotium, Fremont, CA, USA) in the dark at room
temperature. Next, tissues were incubated with a cocktail of
primary antibodies (Supplementary table 2). Subsequently,
they were incubated with a cocktail of secondary
antibodies, followed by incubation with a cocktail of
tertiary antibodies tagged with fluorescence labels.
Afterwards, the tissues were incubated with DAPI for 5 min
as counterstain and sealed. Image cubes were captured at a
Table 1. Clinical characteristics of patients and controls included in the tissue study and the in vitro study
GCA-positive TAB GCA aorta Artherosclerotic aorta GCA PBMCs Healthy control PBMCs
N 11 10 10 10 10
Age (median; years) 74 66 65 72 72
Sex (% female) 70 70 50 70 70
Fulfilled ACR criteria (yes/no) 11/0 NA NA 8/2 NA
Claudication (yes/no) 9/2 NA NA 4/6 NA
Visual ischaemia (yes/no) 4/7 NA NA 1/9 NA
PMR clinic (yes/no) 1/10 NA NA 2/8 NA
CRP (mg L1; median) 66 7 10 38 1.5
ESR (mm h1; median) 83 13 15 73 9
ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; PBMCs,
peripheral blood mononuclear cells; PMR, polymyalgia rheumatica; TAB, temporal artery biopsy.
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magnification of 209 using Nuance Multispectral Imaging
System 3.0.1 (PerkinElmer, Waltham, MA, USA) using
NuanceFX 3.0.1 software (PerkinElmer). All filters available
in the system were utilised to acquire the image cube with
multiple wavelength acquisition (440:460 for DAPI, 490:530
for Alexa 488, 570:600 for Alexa 568, 710:720 for Alexa
647). Spectral unmixing was performed with spectral
libraries of each fluorophore assigned different colours
(DAPI = blue, Alexa 488 = green, Alexa 568 = red, Alexa
647 = yellow), subtracting the background
autofluorescence. Colocalisation of the three fluorophores
was analysed and assigned the colour cyan.
Monocytes and monocyte-derived
macrophages in vitro
Giant cell arteritis and HC monocytes were isolated from
thawed PBMCs by negative selection using the EasySep
monocyte enrichment kit (Stemcell, Vancouver, BC,
Canada), which does not deplete CD16+ monocytes.
Isolated monocytes were analysed by flow cytometry or
cultured for 7 days in DMEM containing 2 mM glutamine,
60 µg mL1 penicillin–streptomycin and 10% FCS in the
presence of 100 ng mL1 GM-CSF (Peprotech, Rocky Hill,
CT, USA) to generate GM-MØs or 100 ng mL1 M-CSF
(Peprotech) to generate M-MØs. The medium was replaced
on the second and fourth day. On day 7, after collecting
the supernatants for Luminex assay, monocyte-derived
macrophages were harvested using citrate saline (135 mM
potassium chloride, 15 mM sodium citrate and 1 mM EDTA)
for 15 min at 37°C. For macrophage activation experiments,
monocytes were cultured for 7 days in the same medium in
the presence of GM-CSF/M-CSF. The medium was replaced
on the third and fifth days. LPS (100 ng mL1) (Sigma-
Aldrich, St. Louis, MO, USA) was added to the culture
during the fifth day medium change. On day 7,
supernatants were collected for ELISA.
Flow cytometry
Phenotyping of monocytes and monocyte-derived
macrophages was performed by flow cytometry using
fluorochrome-conjugated monoclonal antibodies specific
for HLA-DR (FITC, BD Biosciences Franklin Lakes, NJ, USA),
CD14 (Pacific Orange, Thermo Fisher Scientific), CD16
(BUV737, BD), CD64 (APC-Cy7, Biolegend, San Diego, CA,
USA), CD86 (BV711, BD), CD206 (PE-Cy7, Biolegend) and FRb
(APC, Biolegend). The expression of the GM-CSF receptor
(BV650, BD) and the M-CSF receptor (PE-Cy7, Biolegend) on
monocyte subsets was analysed by a separate flow
cytometry panel (including the aforementioned CD14, CD16
and HLA-DR antibodies). Cells were measured on LSR-II (BD)
flow cytometer. For comparison of the mean fluorescence
intensity between experiments, the LSR-II flow cytometer
was calibrated for each run using FACSDiva CS&T research
beads (BD). Data were analysed using Kaluza software (BD).
Monocytes and macrophages were gated by FSC/SSC,
doublets were excluded, and dead cells were excluded
using Zombie dye (Biolegend). To exclude contaminating
lymphocytes in the monocyte gate, cells negative for both
HLA-DR and CD14 were gated out. Monocyte subsets were
gated based on CD14 and CD16 expression.6 Gating
strategy plots are available as Supplementary figure 6.
Luminex assay and ELISA
Supernatants from the GM-MØ and M-MØ cultures (non-
activated and activated) were stored at 20°C until further
use. In supernatants of non-activated cultures, levels of IL-
1b, IL-6, IL-10, IL-12, IL-23 and MMP-9 were measured with
Human premix Magnetic Luminex screening assay kits (R&D
Systems, Abingdon, UK) according to the manufacturer’s
instructions and read on a Luminex Magpix instrument
(Luminex, Austin, TX, USA). Data were analysed with
xPONENT 4.2 software (Luminex). PDGF-AA concentrations
in the supernatant of activated cultures were measured
with the Human PDGF-AA Duo set ELISA (DY-221, R&D
Systems) according to the manufacturer’s instruction. For
calculation and graphing purposes of the PDGF data, data
points below the detection limit of 3.5 pg mL1 were
included and assigned the value of 1.75 pg mL1.
Supernatant levels were corrected for the macrophage cell
count at the time of harvesting and are expressed as ng
mL1 per 50 000 cells.
RNA extraction and qPCR
Total RNA was extracted from healthy donor-derived GM-
MØs and M-MØs using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). Total RNA was reverse transcribed with
SuperScript III reverse transcriptase (Invitrogen, Carlsbad,
CA, USA) with random hexamers (Promega, Madison, WI,
USA). Real-time qPCR was conducted with a ViiATM 7 Real-
Time PCR System with TaqManTM probes (Thermo Fisher)
targeting M-CSF (CSF1, Hs00174164_m1) and GM-CSF (CSF2,
Hs00929873_m1). Amplification plots were analysed with
QuantStudioTM Real-Time PCR software v1.3 (Applied
Biosystems, Foster City, CA, USA). Relative gene expression
was normalised to b-actin (ACTB, Hs99999903_m1) as an
internal control.
Statistics
To analyse the differences between HC and GCA, GM-MØ
and M-MØ in the in vitro study, nonparametric Mann–
Whitney U-tests (two-tailed) were used. Differences in FRb
expression scores for the inner intima between patients
with low and high vessel occlusion scores were also assessed
by Mann–Whitney U-tests. Differences between the results
of GM-MØ and M-MØ raised from the same donor were
analysed with the paired Wilcoxon signed-rank test.
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